- Home
- WKSP vs PHGE Comparison
WKSP vs PHGE Comparison
Compare WKSP & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- PHGE
- Stock Information
- Founded
- WKSP 2003
- PHGE 2015
- Country
- WKSP United States
- PHGE Israel
- Employees
- WKSP N/A
- PHGE N/A
- Industry
- WKSP Auto Parts:O.E.M.
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- PHGE Health Care
- Exchange
- WKSP Nasdaq
- PHGE Nasdaq
- Market Cap
- WKSP 14.7M
- PHGE 14.6M
- IPO Year
- WKSP N/A
- PHGE N/A
- Fundamental
- Price
- WKSP $2.84
- PHGE $0.49
- Analyst Decision
- WKSP Strong Buy
- PHGE Strong Buy
- Analyst Count
- WKSP 3
- PHGE 2
- Target Price
- WKSP $12.83
- PHGE $20.00
- AVG Volume (30 Days)
- WKSP 291.2K
- PHGE 85.8K
- Earning Date
- WKSP 05-15-2025
- PHGE 05-15-2025
- Dividend Yield
- WKSP N/A
- PHGE N/A
- EPS Growth
- WKSP N/A
- PHGE N/A
- EPS
- WKSP N/A
- PHGE N/A
- Revenue
- WKSP $10,211,747.00
- PHGE N/A
- Revenue This Year
- WKSP $227.66
- PHGE N/A
- Revenue Next Year
- WKSP $52.23
- PHGE N/A
- P/E Ratio
- WKSP N/A
- PHGE N/A
- Revenue Growth
- WKSP 407.96
- PHGE N/A
- 52 Week Low
- WKSP $2.44
- PHGE $0.46
- 52 Week High
- WKSP $12.00
- PHGE $4.90
- Technical
- Relative Strength Index (RSI)
- WKSP 45.47
- PHGE 35.69
- Support Level
- WKSP $2.46
- PHGE $0.50
- Resistance Level
- WKSP $3.03
- PHGE $0.57
- Average True Range (ATR)
- WKSP 0.27
- PHGE 0.04
- MACD
- WKSP 0.02
- PHGE -0.00
- Stochastic Oscillator
- WKSP 31.93
- PHGE 24.31
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).